<DOC>
	<DOCNO>NCT02510781</DOCNO>
	<brief_summary>Docetaxel plus carboplatin trastuzumab standard treatment patient human epidermal growth factor receptor-2（HER-2）positive . The investigator witness high pathological complete remission ( pCR ) rate obvious increase cardiac toxicity use anthracycline instead carboplatin . The investigator expect carry large sample size clinical research optimize exist therapeutic regimen</brief_summary>
	<brief_title>A Study Neoadjuvant Therapy Her-2 Positive Breast Cancer Prognosis Detecting CTCs</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>18≤aged＜70 pathologic diagnosis invasive breast cancer，staging ii iii，the diameters≥2cm indicate MRI axillary lymph node（+） Immunohistochemical（IHC） positive 3+ FISH（+） clear hormone receptor（HR） status Eastern cooperative oncology group ( ECOG ) =0/1 LVEF≥55 % pathologic grade Miller Payne screen laboratory value follow parameters：absolute neutrophil acount：≥1500/mm3 , total bilirubin : ≤2.0×ULM , Aspartate transaminase ( AST ) /ALT≤2.5×ULM , platelet≥80000/mm3，serum creatinine≤1.5×ULM pregnant nursing sign Informed consent form prior exposure treatment breast cancer inflammatory/Bilateral/IV stage breast cancer poor physical condition pregnant nursing Cardiac risk（Congestive heart failure、arrhythmia、myocardial infarct、Refractory hypertension（systolic pressure＞180mmHg/diastolic pressure＞100mmHg）） cancer within 5 year prior screen exception cervical carcinoma non melanoma skin cancer Allergic chemotherapy drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>